Preventing and Monitoring for Tumor Lysis Syndrome and Other Toxicities of Venetoclax During Treatment of Chronic Lymphocytic Leukemia

Overview

Journal Hematology Am Soc Hematol Educ Program

Specialty Hematology

Date 2020 Dec 4

PMID 33275717

Citations 14

Authors

Kirsten Fischer

Othman Al-Sawaf

Michael Hallek

Affiliations

Soon will be listed here.

Abstract

Recent developments in the management of chronic lymphocytic leukemia (CLL) have moved the standard of care away from chemoimmunotherapy to targeted agents such as oral kinase inhibitors or BCL-2 antagonists, alone or in combination with anti-CD20 antibodies. Two different treatment approaches have evolved: continuous, indefinite treatment and, more recently, fixed-duration combination treatment. With venetoclax-based treatment, there is a requirement to follow the established guidelines for close monitoring during initiation and ramp up, to reduce the risk of tumor lysis syndrome. The patient's risk should be assessed before the initiation of venetoclax. Appropriate management strategies should be used, including uricosuric agents, hydration, and routine laboratory monitoring, per guidelines. With early identification, immediate management, and dose adjustments, we suggest that tumor lysis syndrome and other toxicities, such as neutropenia and infections, with venetoclax-based treatment can be dealt with successfully.

Citing Articles

Upfront fixed-duration treatment strategies for chronic lymphocytic leukemia in Arab populations: a position statement from the Gulf region.

Yassin M, Al Farsi K, Hamad A, Ghasoub R, Alhuraiji A, Mheidly K Front Med (Lausanne). 2025; 12:1509074.

PMID: 40078401 PMC: 11897515. DOI: 10.3389/fmed.2025.1509074.

Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice.

Timofeeva N, Jain N, Gandhi V Blood Neoplasia. 2025; 1(3).

PMID: 39949788 PMC: 11823466. DOI: 10.1016/j.bneo.2024.100034.

Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia.

Puckrin R, Owen C, Peters A Eur J Haematol. 2024; 114(4):636-640.

PMID: 39726364 PMC: 11880966. DOI: 10.1111/ejh.14376.

Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance.

Ito T, Kamimura T, Kiguchi T, Kato K, Takenaka R, Kobayashi M Int J Hematol. 2024; 120(5):613-620.

PMID: 39167348 PMC: 11513738. DOI: 10.1007/s12185-024-03832-x.

Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies.

Peng X, Tang F, Li Y, Bai J, Li L, Zhang L Discov Oncol. 2024; 15(1):311.

PMID: 39060763 PMC: 11282050. DOI: 10.1007/s12672-024-01161-3.

References

Hoechstetter M, Busch R, Eichhorst B, Buhler A, Winkler D, Eckart M . Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017; 31(12):2833-2837. DOI: 10.1038/leu.2017.246. View

Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour J, Munir T . Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016; 17(6):768-778. DOI: 10.1016/S1470-2045(16)30019-5. View

Lakshmaiah K, Asati V, K G, D L, Abraham Jacob L, M C S . Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2018; 100(6):644-648. DOI: 10.1111/ejh.13068. View

Fischer K, Al-Sawaf O, Bahlo J, Fink A, Tandon M, Dixon M . Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019; 380(23):2225-2236. DOI: 10.1056/NEJMoa1815281. View

Cartron G, de Guibert S, Dilhuydy M, Morschhauser F, Leblond V, Dupuis J . Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014; 124(14):2196-202. DOI: 10.1182/blood-2014-07-586610. View

Cairo M, Coiffier B, Reiter A, Younes A . Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010; 149(4):578-86. DOI: 10.1111/j.1365-2141.2010.08143.x. View

Roeker L, Fox C, Eyre T, Brander D, Allan J, Schuster S . Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019; 25(14):4264-4270. PMC: 8020996. DOI: 10.1158/1078-0432.CCR-19-0361. View

Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink A, Robrecht S . Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020; 21(9):1188-1200. DOI: 10.1016/S1470-2045(20)30443-5. View

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G . Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019; 380(22):2095-2103. PMC: 11827445. DOI: 10.1056/NEJMoa1900574. View

10.

Herling C, Cymbalista F, Gross-Ophoff-Muller C, Bahlo J, Robrecht S, Langerbeins P . Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia. 2020; 34(8):2038-2050. PMC: 7387319. DOI: 10.1038/s41375-020-0747-7. View

11.

Mughal T, Ejaz A, Foringer J, Coiffier B . An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev. 2009; 36(2):164-76. DOI: 10.1016/j.ctrv.2009.11.001. View

12.

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

13.

Woyach J, Ruppert A, Heerema N, Zhao W, Booth A, Ding W . Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018; 379(26):2517-2528. PMC: 6325637. DOI: 10.1056/NEJMoa1812836. View

14.

McBride A, Trifilio S, Baxter N, Gregory T, Howard S . Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies. J Adv Pract Oncol. 2018; 8(7):705-720. PMC: 6188097. View

15.

Seymour J, Kipps T, Eichhorst B, Hillmen P, DRozario J, Assouline S . Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018; 378(12):1107-1120. DOI: 10.1056/NEJMoa1713976. View

16.

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

17.

Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R . Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998; 338(21):1506-14. DOI: 10.1056/NEJM199805213382104. View

18.

Davids M, Hallek M, Wierda W, Roberts A, Stilgenbauer S, Jones J . Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018; 24(18):4371-4379. DOI: 10.1158/1078-0432.CCR-17-3761. View

19.

Shanafelt T, Wang X, Kay N, Hanson C, OBrien S, Barrientos J . Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2019; 381(5):432-443. PMC: 6908306. DOI: 10.1056/NEJMoa1817073. View

20.

Flinn I, Gribben J, Dyer M, Wierda W, Maris M, Furman R . Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019; 133(26):2765-2775. PMC: 6706803. DOI: 10.1182/blood-2019-01-896290. View